Landscape Capital Management L.L.C. Makes New $1.72 Million Investment in Sarepta Therapeutics, Inc. $SRPT

Landscape Capital Management L.L.C. bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, Holdings Channel reports. The institutional investor bought 79,671 shares of the biotechnology company’s stock, valued at approximately $1,715,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SRPT. Vanguard Group Inc. lifted its stake in Sarepta Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares during the last quarter. First Trust Advisors LP lifted its stake in Sarepta Therapeutics by 209.1% during the third quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after purchasing an additional 1,312,220 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Sarepta Therapeutics by 183.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock worth $33,627,000 after purchasing an additional 1,129,610 shares during the last quarter. Erste Asset Management GmbH lifted its stake in Sarepta Therapeutics by 65.7% during the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock worth $50,588,000 after purchasing an additional 1,064,530 shares during the last quarter. Finally, Braidwell LP bought a new stake in Sarepta Therapeutics during the third quarter worth $16,035,000. 86.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SRPT has been the subject of several recent analyst reports. Loop Capital set a $25.00 target price on Sarepta Therapeutics in a research note on Tuesday, March 3rd. Wells Fargo & Company lowered their price target on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings upgraded shares of Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday. Finally, HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a report on Thursday, April 16th. Eight investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus price target of $24.77.

Sarepta Therapeutics Stock Up 3.0%

Shares of NASDAQ:SRPT opened at $15.77 on Tuesday. The company has a fifty day moving average of $19.08 and a 200-day moving average of $19.73. The company has a market capitalization of $1.66 billion, a PE ratio of -16.43, a price-to-earnings-growth ratio of 0.16 and a beta of 0.21. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 4.63. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. The company had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($3.42) earnings per share. On average, equities analysts predict that Sarepta Therapeutics, Inc. will post 3.99 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.